Literature DB >> 7579091

Pharmacokinetics of fluconazole in renal failure.

T Berl1, K D Wilner, M Gardner, R A Hansen, B Farmer, B A Baris, W L Henrich.   

Abstract

Fluconazole (FLU) is a widely used antifungal agent. The multiple-dose pharmacokinetics of FLU in renal impairment have not been previously investigated. The following groups were studied: volunteers with creatinine clearances (CLcr, > 50 mL/min) of 107 mL/min, given a loading dose of 400 mg and a daily dose of 200 mg/day for 9 days (Group 1); subjects with CLcr between 21 and 50 mL/min with a mean of 38 mL/min, given a loading dose of 200 mg and a maintenance dose of 100 mg/day for 9 days (Group 2); subjects with CLcr between 11 and 20 mL/min with a mean of 14.8 ml/min, given a loading dose of 100 mg and a maintenance dose of 50 mg/day for 9 days (Group 3); and subjects on hemodialysis (three times per week) receiving a loading dose of 200 mg and then 100 mg after each of four dialysis sessions (Group 4) (N = 10 per group). After the administration of the loading dose on Day 1, the mean area under the curve (AUC) (0-24) measurements were approximately proportional to the dose of FLU and independent of renal function. After 10 days of FLU dosing, the mean renal clearance of FLU decreased as CLcr decreased for Groups 1 to 3, and the Day 10 mean half-lives were inversely related to mean CLcr (36.7 h in Group 1, 84.5 h in Group 2, and 101.9 h in Group 3). The mean AUC (0-24) on Day 10 was similar for Group 1 compared with Group 2, despite a reduction in the maintenance dose by 50%. (ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579091     DOI: 10.1681/ASN.V62242

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  12 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 2.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

3.  Population pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with Candida infection.

Authors:  Seunghoon Han; Jimyon Kim; Haejun Yim; Jun Hur; Wonkeun Song; Jongtae Lee; Sangil Jeon; Taegon Hong; Heungjeong Woo; Dong-Seok Yim
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

4.  Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration.

Authors:  Kazuaki Yagasaki; Satoshi Gando; Naoyuki Matsuda; Takashi Kameue; Toshiteru Ishitani; Takeshi Hirano; Ken Iseki
Journal:  Intensive Care Med       Date:  2003-09-13       Impact factor: 17.440

5.  The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.

Authors:  Satoshi Sobue; Keith Tan; Gary Layton; Violette Leclerc; Angelika Weil
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

6.  Fluconazole Pharmacokinetics in Galleria mellonella Larvae and Performance Evaluation of a Bioassay Compared to Liquid Chromatography-Tandem Mass Spectrometry for Hemolymph Specimens.

Authors:  Karen Marie Thyssen Astvad; Joseph Meletiadis; Sarah Whalley; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 7.  The use of antifungal therapy in neonatal intensive care.

Authors:  Daniela Testoni; P Brian Smith; Daniel K Benjamin
Journal:  Clin Perinatol       Date:  2012-01-11       Impact factor: 2.642

8.  Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.

Authors:  Mahipal G Sinnollareddy; Jason A Roberts; Jeffrey Lipman; Murat Akova; Matteo Bassetti; Jan J De Waele; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; George Dimopoulos
Journal:  Crit Care       Date:  2015-02-04       Impact factor: 9.097

Review 9.  Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective.

Authors:  Michel Laverdiere; Eric J Bow; Coleman Rotstein; Julie Autmizguine; Raewyn Broady; Gary Garber; Shariq Haider; Trana Hussaini; Shahid Husain; Philippe Ovetchkine; Jack T Seki; Yves Théorêt
Journal:  Can J Infect Dis Med Microbiol       Date:  2014 Nov-Dec       Impact factor: 2.471

10.  External Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models.

Authors:  Michael F Hwang; Ryan J Beechinor; Kelly C Wade; Daniel K Benjamin; P Brian Smith; Christoph P Hornik; Edmund V Capparelli; Shahnaz Duara; Kathleen A Kennedy; Michael Cohen-Wolkowiez; Daniel Gonzalez
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.938

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.